Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BMS-986209 in Healthy Participants
NCT04154800Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986209 in thrombosis (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs) including bleeding up to 18 days, Incidence of serious AEs (SAEs) up to 44 days and 4 more. Started Dec 2019; status: completed.
02
Drugs
BMS-986209
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04154800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154800.